{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:24:26Z","timestamp":1764332666259,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Hodges Society at the University of Chicago"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00330-018-5533-9","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T06:23:12Z","timestamp":1530512592000},"page":"682-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-4477","authenticated-orcid":false,"given":"Eyjolfur","family":"Gudmundsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zacariah","family":"Labby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Sensakovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buerkley","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Cunliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Samuel G.","family":"Armato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"5533_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","volume":"78","author":"JP Meerbeeck van","year":"2011","unstructured":"van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P (2011) Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol 78:92\u2013111","journal-title":"Crit Rev Oncol Hematol"},{"key":"5533_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"BNJ Vogelzang","year":"2008","unstructured":"Vogelzang BNJ, Rusthoven JJ, Symanowski J et al (2008) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"key":"5533_CR3","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1148\/rg.346130089","volume":"34","author":"LT Nickell","year":"2014","unstructured":"Nickell LT, Lichtenberger Iii JP, Khorashadi L et al (2014) Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics 34:1692\u20131706","journal-title":"Radiographics"},{"key":"5533_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257\u2013260","journal-title":"Ann Oncol"},{"key":"5533_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"5533_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2005.12.013","volume":"52","author":"GR Oxnard","year":"2006","unstructured":"Oxnard GR, Armato SG III, Kindler HL (2006) Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 52:141\u2013148","journal-title":"Lung Cancer"},{"key":"5533_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/JTO.0b013e3181dd0ef1","volume":"5","author":"F Liu","year":"2010","unstructured":"Liu F, Zhao B, Krug LM et al (2010) Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol 5:879\u2013884","journal-title":"J Thorac Oncol"},{"key":"5533_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1183\/09031936.00146110","volume":"38","author":"T Frauenfelder","year":"2011","unstructured":"Frauenfelder T, Tutic M, Weder W et al (2011) Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J 38:162\u2013168","journal-title":"Eur Respir J"},{"key":"5533_CR9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/annonc\/mds535","volume":"24","author":"ZE Labby","year":"2013","unstructured":"Labby ZE, Nowak AK, Dignam JJ et al (2013) Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol 24:999\u20131005","journal-title":"Ann Oncol"},{"key":"5533_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctrv.2014.10.007","volume":"41","author":"J Remon","year":"2015","unstructured":"Remon J, Reguart N, Corral J, Lianes P (2015) Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev 41:27\u201334","journal-title":"Cancer Treat Rev"},{"key":"5533_CR11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR et al (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509\u20132515","journal-title":"J Clin Oncol"},{"key":"5533_CR12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J et al (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405\u20131414","journal-title":"Lancet"},{"key":"5533_CR13","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"5533_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/annonc\/mdp466","volume":"21","author":"R Thiam","year":"2010","unstructured":"Thiam R, Fournier LS, Trinquart L et al (2010) Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 21:936\u2013941","journal-title":"Ann Oncol"},{"key":"5533_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2214\/AJR.11.7483","volume":"198","author":"M Nishino","year":"2012","unstructured":"Nishino M, Jagannathan JP, Krajewski KM et al (2012) Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198:737","journal-title":"AJR Am J Roentgenol"},{"key":"5533_CR16","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.ejrad.2015.03.022","volume":"84","author":"D Prezzi","year":"2015","unstructured":"Prezzi D, Khan A, Goh V (2015) Perfusion CT imaging of treatment response in oncology. Eur J Radiol 84:2380\u20132385","journal-title":"Eur J Radiol"},{"key":"5533_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00004424-199311001-00023","volume":"28","author":"MJ Blomley","year":"1993","unstructured":"Blomley MJ, Coulden R, Bufkin C et al (1993) Contrast bolus dynamic computed tomography for the measurement of solid organ perfusion. Invest Radiol 28:72\u201377","journal-title":"Invest Radiol"},{"key":"5533_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1259\/bjr\/13564625","volume":"76","author":"KA Miles","year":"2003","unstructured":"Miles KA, Griffiths MR (2003) Perfusion CT: a worthwhile enhancement? Br J Radiol 76:220\u2013231","journal-title":"Br J Radiol"},{"key":"5533_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/JTO.0000000000000376","volume":"10","author":"S Sudarski","year":"2015","unstructured":"Sudarski S, Shi J, Schmid-Bindert G et al (2015) Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy. J Thorac Oncol 10:164\u2013171","journal-title":"J Thorac Oncol"},{"key":"5533_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/RCT.0b013e318245c23c","volume":"36","author":"L Yang","year":"2012","unstructured":"Yang L, Zhang X, Tan B et al (2012) Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma. J Comput Assist Tomogr 36:226\u2013230","journal-title":"J Comput Assist Tomogr"},{"key":"5533_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2214\/AJR.09.3462","volume":"194","author":"JA Christner","year":"2010","unstructured":"Christner JA, Kofler JM, McCollough CH (2010) Estimating effective dose for CT using dose\u2013length product compared with using organ doses: consequences of adopting International Commission on Radiological Protection Publication 103 or dual-energy scanning. Am J Roentgenol 194:881\u2013889","journal-title":"Am J Roentgenol"},{"key":"5533_CR22","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1148\/radiol.2483071964","volume":"248","author":"W Huda","year":"2008","unstructured":"Huda W, Ogden KM, Khorasani MR (2008) Converting dose-length product to effective dose at CT. Radiology 248:995\u20131003","journal-title":"Radiology"},{"key":"5533_CR23","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.neuroimage.2010.09.025","volume":"54","author":"BB Avants","year":"2011","unstructured":"Avants BB, Tustison NJ, Song G et al (2011) A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54:2033\u20132044","journal-title":"Neuroimage"},{"key":"5533_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1148\/radiology.137.3.7003648","volume":"137","author":"L Axel","year":"1980","unstructured":"Axel L (1980) Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology 137:679\u2013686","journal-title":"Radiology"},{"key":"5533_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1148\/radiology.209.1.9769817","volume":"209","author":"M Koenig","year":"1998","unstructured":"Koenig M, Klotz E, Luka B et al (1998) Perfusion CT of the brain: diagnostic approach for early detection of ischemic stroke. Radiology 209:85\u201393","journal-title":"Radiology"},{"key":"5533_CR26","unstructured":"Hodges JL Jr, Lehmann EL (1963) Estimates of location based on rank tests. Ann Math Stat 598\u2013611"},{"key":"5533_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/01621459.1972.10481279","volume":"67","author":"DF Bauer","year":"1972","unstructured":"Bauer DF (1972) Constructing confidence sets using rank statistics. J Am Stat Assoc 67:687\u2013690","journal-title":"J Am Stat Assoc"},{"key":"5533_CR28","unstructured":"Abdi H (2007) The Bonferonni and \u0160id\u00e1k corrections for multiple comparisons. Enc Meas Stat 3:103\u2013107"},{"key":"5533_CR29","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00330-006-0425-9","volume":"17","author":"MR Meijerink","year":"2007","unstructured":"Meijerink MR, van Cruijsen H, Hoekman K et al (2007) The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 17:1700\u20131713","journal-title":"Eur Radiol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-018-5533-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5533-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5533-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T16:53:45Z","timestamp":1581958425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-018-5533-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["5533"],"URL":"https:\/\/doi.org\/10.1007\/s00330-018-5533-9","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"type":"print","value":"0938-7994"},{"type":"electronic","value":"1432-1084"}],"subject":[],"published":{"date-parts":[[2018,7,2]]},"assertion":[{"value":"19 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Samuel G. Armato III, Ph.D., at the University of Chicago.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: SGA receives royalties and licensing fees for computer-aided diagnostic technology through the University of Chicago. SGA is a consultant for Aduro Biotech, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional review board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 prospective\u2022 diagnostic or prognostic study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}